As of 2007,<unk>  is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. The other chemotherapy regimens that are widely used in this setting is the Stanford V and BEACOPP regimens. Administration One cycle of<unk>  chemotherapy is typically given over 4 weeks in two doses, with the first on day 1 and the second dose on day 15. All four of the chemotherapy drugs are given intravenously.<unk>  chemotherapy is usually given in the outpatient setting — that is, it does not require hospitalization. Typical dosages for one 28-day cycle of<unk>  are: Drug Dose Mode Days Adriamycin 25 mg/m2 IV bolus Days 1 and 15 Bleomycin 10 IU/m2 IV bolus Days 1 and 15 Vinblastine 6 mg/m2 IV bolus Days 1 and 15 Dacarbazine 375 mg/m2 IV infusion Days 1 and 15 The number of cycles given depends upon the stage of the disease and how well the patient tolerates chemotherapy. Doses may be delayed because of neutropenia, thrombocytopenia, or other side effects. A FDG PET scan is commonly advised following the completion of<unk>  to assess response to the therapy. Interim PET (following 2 cycles) may be useful in aiding prognostication, but does not yet guide changes in therapy except within clinical trial protocols.
ABVD
CAREN
SWAP-200
PAIR 
SBAR
PVSRIPO
Birmingham gauge
Sampaolesi line